Literature DB >> 28270697

Liver: Taking out the JuNK to treat α1-antitrypsin deficiency.

S Tamir Rashid1, David A Lomas2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28270697     DOI： 10.1038/nrgastro.2017.22

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  The mechanism of Z alpha 1-antitrypsin accumulation in the liver.

Authors:  D A Lomas; D L Evans; J T Finch; R W Carrell
Journal:  Nature       Date:  1992-06-18       Impact factor: 49.962

2.  An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis.

Authors:  Tunda Hidvegi; Michael Ewing; Pamela Hale; Christine Dippold; Caroline Beckett; Carolyn Kemp; Nicholas Maurice; Amitava Mukherjee; Christina Goldbach; Simon Watkins; George Michalopoulos; David H Perlmutter
Journal:  Science       Date:  2010-06-03       Impact factor: 47.728

3.  Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice.

Authors:  J A Carlson; B B Rogers; R N Sifers; M J Finegold; S M Clift; F J DeMayo; D W Bullock; S L Woo
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

4.  A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency.

Authors:  Elena Miranda; Juan Pérez; Ugo I Ekeowa; Nedim Hadzic; Noor Kalsheker; Bibek Gooptu; Bernard Portmann; Didier Belorgey; Marian Hill; Susan Chambers; Jeff Teckman; Graeme J Alexander; Stefan J Marciniak; David A Lomas
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  Accumulation of the insoluble PiZ variant of human alpha 1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP.

Authors:  K S Graham; A Le; R N Sifers
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

6.  Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1-antitrypsin.

Authors:  Prakash Baligar; Veena Kochat; Shailendra K Arindkar; Zaffar Equbal; Snehashish Mukherjee; Swati Patel; Perumal Nagarajan; Sujata Mohanty; Jeffrey H Teckman; Asok Mukhopadhyay
Journal:  Hepatology       Date:  2017-02-25       Impact factor: 17.425

Review 7.  Bone marrow stem cell therapy for liver disease.

Authors:  Andrew King; Philip N Newsome
Journal:  Dig Dis       Date:  2014-07-14       Impact factor: 2.404

Review 8.  Update on alpha-1 antitrypsin deficiency: New therapies.

Authors:  David A Lomas; John R Hurst; Bibek Gooptu
Journal:  J Hepatol       Date:  2016-03-29       Impact factor: 25.083

9.  Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.

Authors:  Kosuke Yusa; S Tamir Rashid; Helene Strick-Marchand; Ignacio Varela; Pei-Qi Liu; David E Paschon; Elena Miranda; Adriana Ordóñez; Nicholas R F Hannan; Foad J Rouhani; Sylvie Darche; Graeme Alexander; Stefan J Marciniak; Noemi Fusaki; Mamoru Hasegawa; Michael C Holmes; James P Di Santo; David A Lomas; Allan Bradley; Ludovic Vallier
Journal:  Nature       Date:  2011-10-12       Impact factor: 49.962

10.  Activation of the c-Jun N-terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin.

Authors:  Nunzia Pastore; Sergio Attanasio; Barbara Granese; Raffaele Castello; Jeffrey Teckman; Andrew A Wilson; Andrea Ballabio; Nicola Brunetti-Pierri
Journal:  Hepatology       Date:  2017-04-10       Impact factor: 17.425
  10 in total
  1 in total

1.  New Therapeutic Targets for Alpha-1 Antitrypsin Deficiency.

Authors:  David A Lomas
Journal:  Chronic Obstr Pulm Dis       Date:  2018-08-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.